Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Synchrony Financial (SYF) Price & Performance

BioNTech SE - ADRTrade
Synchrony FinancialTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Synchrony Financial — how do they compare? BioNTech SE - ADR trades at $93.1 (market cap $23.31B), while Synchrony Financial trades at $78.44 (market cap $25.53B). The key difference: BioNTech SE - ADR and Synchrony Financial are close in size by market cap, and Synchrony Financial pays a 1.73% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXSYF
Market Cap
$23.31B$25.53B
Sector
HealthFinancials
52-Week High
$119.34$88.47
52-Week Low
$83.89$63.78
Enterprise Value
$6.60B
Dividend Yield
1.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

Synchrony Financial

Synchrony Financial (SYF) trades at $78.25, up 0.08% on the day, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The stock shows robust fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent revenue around $15.0B. Recent news highlights partnerships like CareCredit with Stripe and aggressive share buybacks, while analyst consensus is strongly positive with a $86.33 price target.

The outlook for SYF is favorable due to undervaluation, earnings growth, and shareholder returns via dividends and buybacks. Risks include economic sensitivity to consumer spending and rising expenses. With no sell ratings from analysts and institutional confidence, the stock presents a solid opportunity for value-oriented investors seeking financial sector exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF